RecruitingPhase 2NCT07413354

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Studying Adult hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Intervention
Tislelizumab plus Huaier granule(drug)
Enrollment
94 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07413354 on ClinicalTrials.gov

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adult hepatocellular carcinoma

← Back to all trials